# AMGN — Amgen · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** AMGN  
**Sources:** 19  
**Published:** 2026-11-02  
**Canonical:** https://app.k3vl4r.com/research/deep-research-amgn-amgen-catalysts-narrative-risks-5915

---

# Amgen Inc. (AMGN) — Research Snapshot as of 2026-11-02

*Not investment advice.* Below is a point-in-time research summary based on the sources provided. All figures reflect the reporting as stated in each source; where sources conflict, the discrepancy is noted.

## 1. Recent Catalysts (last ~1–3 months)

**DeLLphi-305 clinical readout (IMDELLTRA/tarlatamab + IMFINZI/durvalumab) — Oct 24, 2026**
Amgen announced that adding IMDELLTRA to IMFINZI reduced the hazard of death by 58% versus IMFINZI alone in a Phase 3 trial for extensive-stage small-cell lung cancer (ES-SCLC) that had not progressed after initial durvalumab and chemotherapy. Reported figures included a median survival of 21.1 months vs. 12.7 months, and ~80% vs. 53% one-year survival. Amgen described these as interim outcomes, not guaranteed patient benefits, and the catalyst concerns an earlier treatment setting rather than a new approval. [[1]](https://www.techi.com/amgen-stock-forecast-imdelltra-survival/)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-amgn-amgen-catalysts-narrative-risks-5915 (free to sign up)._